LEMS drug

A drug approved in Europe to treat Lambert-Eaton myasthenic syndrome is now being tested in the United States; clinical trial participants sought

posted on November 18, 2011 - 6:00am
BioMarin Pharmaceutical of Novato, Calif., is conducting a multicenter study of 3,4-diaminopyridine phosphate (3,4-DAP), also known as amifampridine phosphate, in adults with Lambert-Eaton myasthenic syndrome (LEMS). There are eight U.S. trial sites, with additional sites planned for France, Germany, Italy, Poland and Spain.

New content is being added every day. Please check back again.